Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 4
2011 2
2012 12
2013 37
2014 22
2015 5
2016 1
2017 2
2018 3
2019 4
2020 3
2021 3
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Blauvelt A, et al. Among authors: ladizinski b. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. JAMA Dermatol. 2021. PMID: 34347860 Free PMC article. Clinical Trial.
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Blauvelt A, Ladizinski B, Prajapati VH, Laquer V, Fischer A, Eisman S, Hu X, Wu T, Calimlim BM, Kaplan B, Liu Y, Teixeira HD, Liu J, Eyerich K. Blauvelt A, et al. Among authors: ladizinski b. J Am Acad Dermatol. 2023 Sep;89(3):478-485. doi: 10.1016/j.jaad.2023.05.033. Epub 2023 May 23. J Am Acad Dermatol. 2023. PMID: 37230366 Free article. Clinical Trial.
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Paller AS, et al. Among authors: ladizinski b. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. JAMA Dermatol. 2023. PMID: 37043227 Free PMC article. Clinical Trial.
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A, Rosmarin D, Lynde C, Liu J, Gamelli A, Zeng J, Ladizinski B, Chu AD, Reich K. Silverberg JI, et al. Among authors: ladizinski b. J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14. J Allergy Clin Immunol. 2022. PMID: 34403658 Free article. Clinical Trial.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR, Ladizinski B, Chu AD, Liu J, Irvine AD. Guttman-Yassky E, et al. Among authors: ladizinski b. J Allergy Clin Immunol. 2023 Jan;151(1):172-181. doi: 10.1016/j.jaci.2022.09.023. Epub 2022 Oct 1. J Allergy Clin Immunol. 2023. PMID: 36195170 Free article.
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Mendes-Bastos P, et al. Among authors: ladizinski b. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. J Am Acad Dermatol. 2022. PMID: 35714786 Free article. Clinical Trial.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Reich K, et al. Among authors: ladizinski b. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21. Lancet. 2021. PMID: 34023009 Clinical Trial.
Lichen amyloidosis.
Ladizinski B, Lee KC. Ladizinski B, et al. CMAJ. 2014 Apr 15;186(7):532. doi: 10.1503/cmaj.130698. Epub 2013 Oct 15. CMAJ. 2014. PMID: 24130236 Free PMC article. Review. No abstract available.
Disseminated Cutaneous Blastomycosis.
Ladizinski B, Piette W. Ladizinski B, et al. N Engl J Med. 2018 Jul 5;379(1):74. doi: 10.1056/NEJMicm1706238. N Engl J Med. 2018. PMID: 29972741 Free article. No abstract available.
93 results